A Phase 2/3 interventional study of nalbuphine HCl ER in Uremic Pruritus and Pruritus, sponsored by Trevi Therapeutics. Completed at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-21.
Sponsored by Trevi Therapeutics · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies in Pruritus with a site in United States — 24 open to participants now, 28 under way, 8 of them phase 3. Pruritus · United States.
Among the 163 studies in Pruritus with a site in United States, this one is the 51st largest by enrollment of the 153 interventional ones that give a count, is one of 9 that started in 2014, is one of 5 in phase 2/3, and was the 44th registered.
491 studies on the registry are indexed under Pruritus; 94 are open to participants now.
Browse Pruritus studies →24 of the 163 studies in Pruritus with a site in United States are open now. Recruiting first, the newest first:
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Novartis Pharmaceuticals · Sites in United States, Canada, China
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Argentina, Canada and 2 more countries
Ages 18+
Paradigm Therapeutics · Sites in United States
Ages 28 days–12 yrs
Integrative Skin Science and Research · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 69 · Phase 3 48 · Phase 4 13
First in 2000; this study’s year is marked. 9 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 167 is above the median of 60 across 423 interventional studies indexed under Pruritus.
Median enrollment 70 across the 153 interventional studies, 80 across the 9 observational. Of the 126 that completed or were terminated, 80 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
108 of 163 have an industry lead sponsor. The 10 most frequent:
Trevi Therapeutics is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Trevi Therapeutics has 5 studies filed under Pruritus — fewer than ten, so there is no comparison to draw.
12 of the studies in Pruritus with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482787Phase 3Paradigm TherapeuticsEfficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | 2027-05-17 |
| NCT05263206Phase 3SanofiEfficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) | 2027-06-02 |
| NCT07450716Massachusetts General HospitalAssessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus | 2026-12 |
| NCT07317271Johns Hopkins UniversityVR-PMR for Post-Burn Symptoms | 2026-12 |
| NCT07074977Galderma R&DProof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO) | 2026-12 |
Add all 12 to your calendar (.ics) → With an account.
Among the 163 studies in Pruritus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
nalbuphine HCl ER titrated from a dose of 30 mg QD to 120 BID for up to 3 weeks based on tolerability and efficacy, then maintained for an additional 21 weeks. Total duration of 24 weeks.
Drug: nalbuphine HCl ER
nalbuphine HCl ER
Also known as: nalbuphine
Number and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs)
The number of participants reporting at least one TEAE of a particular body system and preferred term are reported (incidence)
Time frame: 24 weeks
| Milestone | Nalbuphine HCl ER |
|---|---|
| Started | 167 |
| Completed | 101 |
| Not completed | 66 |
The number of participants reporting at least one TEAE of a particular body system and preferred term are reported (incidence)
| Participants | Nalbuphine HCl ER |
|---|---|
| Number and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs) | 133 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nalbuphine HCl ER | 0/167 (0%) | 54/167 (32.3%) | 0/167 (0%) |
| Event | Nalbuphine HCl ER |
|---|---|
| Arteriovenous graft site infectionInfections and infestations | 4/167 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 4/167 |
| Non-cardiac chest painGeneral disorders | 4/167 |
| SepsisInfections and infestations | 3/167 |
| HypotensionVascular disorders | 3/167 |
| DiverticulitisInfections and infestations | 2/167 |
| PneumoniaInfections and infestations | 2/167 |
| Septic shockInfections and infestations | 2/167 |
| SyncopeNervous system disorders | 2/167 |
| Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 2/167 |
| Age, Continuous(years) | Nalbuphine HCl ER |
|---|---|
| Mean | 53.1 ± 12.2 |
| Sex: Female, Male(Participants) | Nalbuphine HCl ER |
|---|---|
| Female | 75 |
| Male | 92 |
| Ethnicity (NIH/OMB)(Participants) | Nalbuphine HCl ER |
|---|---|
| Hispanic or Latino | 31 |
| Not Hispanic or Latino | 136 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Nalbuphine HCl ER |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 89 |
| White | 73 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Nalbuphine HCl ER |
|---|---|
| United States | 146 |
| Europe | 21 |
The record gives a start of Sep 2014, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2020, 4 years 8 months after primary completion. A results delay was requested in May 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalbuphine